ASP Isotopes

Phase A — Understand the business

Lens 1 · Company Overview

ASP Isotopes is an advanced-materials / isotope-enrichment company that, as of mid-2026, is really a holding company stapling together four very different businesses under one promotional umbrella: (1) specialist isotope enrichment, (2) a nuclear-fuels venture (QLE), (3) a newly acquired South African helium/LNG producer (Renergen), and (4) a downstream radiopharmacy roll-up. It IPO'd on Nasdaq in Nov 2022 and also carries a JSE secondary listing.

The core technology bet is two proprietary enrichment methods: the Aerodynamic Separation Process ("ASP") and Quantum Enrichment ("QE", laser-based). The thesis: Russia (Rosatom) is the incumbent/sole supplier of several critical enriched isotopes, the West wants to de-risk that supply chain, and ASP can be the Western alternative. Initial isotope focus: Carbon-14 (pharma/agrochem tracer; historically Russia-sole-sourced), Silicon-28 (ultra-pure, for advanced semis / silicon-qubit quantum computing), and Ytterbium-176 (feedstock for Lutetium-177 radiotherapeutics).

Crucial state of play (mid-2026): the isotope business has essentially zero isotope revenue. Management states plainly: "We currently have no sales attributable to enriched isotopes" and "We have not generated any revenue from the sale of our enriched isotopes". First commercial shipments of C-14, Si-28 and Yb-176 are all targeted for mid-2026 / Q2–Q3 2026 — i.e., still in the future as of this dossier.

Contract structure / key customers (isotopes): a June 2023 tolling agreement with a Canadian customer for the entire capacity of the C-14 plant; April/June 2024 purchase orders with "a US semiconductor company" and "a global industrial gas company" for Si-28. Web reporting names three Si-28 contracts (two US semis + one industrial gas) shipping 1H26. These are early POs, not long-dated take-or-pay at scale.

The other three businesses:

• QLE (Quantum Leap Energy) — nuclear fuels (HALEU for SMRs, Lithium-6/7 for fusion/LWR). Has a TerraPower loan + 10-yr HALEU supply agreement, an Necsa (South Africa state nuclear co.) services contract, and confidentially filed a draft S-1 in Nov 2025 for a separate IPO/spin to ASPI holders.
• Renergen (acquired Jan 6 2026, all-stock, 14,270,000 ASPI shares) — South Africa's only onshore gas producer; first integrated liquid-helium + LNG producer via 94.5%-owned Tetra4 and the Virginia Gas Project.
• Radiopharmacy — 51% PET Labs (SA), 100% East Coast Nuclear Pharmacy (US, Oct 2025), 60% Numed (Jan 2026). Downstream PET/SPECT dose distribution.

A fourth, now-detached leg — Skyline (Hong Kong civil-engineering contractor) — was consolidated Aug 2025 and deconsolidated Mar 29 2026 (see Lens 5/10). It is the single biggest "tell" in the file.

Lens 2 · Supply Chain

Map the chain per business line; name the actual stakeholders:

Isotopes (ASP/QE):

• Upstream feedstock → for C-14, the customer supplies the feedstock under the tolling model ("We have received an initial supply of feedstock from our customer"). For Si-28, feedstock is silane/disilane-class gases.
• Enrichment → three plants in Pretoria, South Africa: a C-14 (light-isotope) ASP plant, a larger multi-isotope ASP plant (Si-28/Mo-100), and a QE laser plant (Yb-176). The two larger plants were still classified construction-in-progress at 2026-03-31.
• IP origin → assets/IP acquired from Klydon (Pty) Ltd (ASP aerodynamic tech) and Molybdos (acquired in a "business rescue" auction); QE tech developed in-house/UK.
• Downstream → enriched isotope → Lu-177 producers/radiopharma (Yb-176), semiconductor/quantum buyers (Si-28), pharma/agrochem (C-14).
• Chokepoint / single-source dependency it is trying to BREAK: Rosatom is currently the sole commercial supplier of Yb-176 and historically the sole supplier of C-14. ASP's whole reason to exist is being the non-Russian second source. The flip side: ASP itself would be a single Pretoria-site supplier — concentration risk simply relocated.

Nuclear fuels (QLE): feed material/permits (Necsa, DMRE, DOE/NRC, UK ONR/UKAEA) → QE/ASP uranium enrichment (Pelindaba site, Necsa-provided infrastructure) → HALEU → TerraPower (Natrium reactor, Wyoming) as anchor offtake; lithium laser research with the University of Bristol. Note: no U-235 has ever been enriched by the company, nor has it received permission to even test — this chain is entirely prospective.

Helium/LNG (Renergen/Tetra4): gas reserve (Free State, >3% He concentration, >90% CH4, ~7% N2 used as separation aid) → Virginia Gas Plant (liquefaction + He separation to 99.999%) → LNG sold domestically into SA's energy-short market; liquid He sold to global buyers. Financing partners along this chain: US DFC (conditional $500M senior secured for Phase 2), Standard Bank of South Africa (conditional $250M), legacy IDC and original DFC facilities; total committed debt funding cited at $750M. Chokepoint: Phase 2 is a ~$1.16B single-asset construction project dependent on that debt actually funding.

Lens 3 · Competitive Advantages (moats)

The bull moat is narrow but, where it exists, real and specific:

• Yb-176 / Lu-177: the genuinely differentiated position. If ASP achieves commercial-quantity Yb-176, it claims to be "the only supplier of commercial quantities … in the Western world" against a Rosatom monopoly, into a Lu-177 market where Pluvicto consensus >$4B and the beta-emitter market is forecast >$15B/yr within a decade, with documented >2-month patient treatment delays from shortage. Western-sourcing + first-mover + a supply-constrained, high-value end market is a defensible wedge.
• C-14: breaking a Russia-sole-source with a customer-funded tolling model and the entire plant pre-committed is a low-capital, sticky position.
• Process IP: ASP and QE are proprietary; the company argues ASP is uniquely suited to low-molecular-mass molecules (Si/Ge electronic gases).
• Renergen helium grade: >3% He concentration vs. <0.5% typical conventional gas, with coproduced nitrogen as a free separation aid — a structural cost advantage if the plant runs reliably.

Why the moat is thinner than the deck implies:

• HALEU is the opposite of a moat. The entrenched Western players — Centrus (>920 kg HALEU already delivered to DOE; DOE contract extended to 6/30/2026 + 8 yrs of options; +12 MT build-out on a $900M DOE award) and Urenco (NRC-authorized to 10% U-235; Capenhurst LEU+ deliveries on time in 2026) — are years and real kilograms ahead. ASP/QLE has produced zero. On HALEU, ASP is the late, unpermitted entrant.
• Si-28 has credible competitors: Urenco can separate Si-28 at hundreds of kg/yr at 99.9%; Rosatom/Electrochemical Plant produces it cheaply on Soviet-era kit.
• Bargaining power is weak today — the isotope buyers are large semis/industrial-gas/pharma names; ASP is a pre-revenue single-site supplier that needs them more than they need it.

Net: this is a portfolio of optionality, not yet a moated cash machine. The Yb-176 leg is the one I'd underwrite; HALEU is the one the deck oversells.

Lens 4 · Segments

Reported segments shifted twice: 2 segments in 2024 (nuclear fuels; specialist isotopes) → 3 in Aug 2025 with Skyline (added construction) → and in Q1 2026 Skyline was deconsolidated to discontinued operations.

FY2025 segment revenue & net income (loss) before NCI, $000:

The single most important fact on this page: of FY25's $23.8M revenue, $18.2M (76%) was Skyline construction and $5.6M was radiopharmacy doses — $0 was enriched isotopes. And the entire reported profit center (construction, +$17.5M) is the segment they deconsolidated five months after acquiring it. Strip Skyline and the company is a ~$5.6M-revenue radiopharmacy with a giant pre-revenue R&D balance sheet attached. The nuclear-fuels "loss" of $144.1M is almost entirely the non-cash convertible-note fair-value mark (Lens 5/10), not operating spend.

Segment assets FY25: Specialist isotopes $323.7M, Nuclear fuels $94.3M, Construction $80.1M (now largely gone).

Geography: operations are overwhelmingly South Africa (enrichment + helium/LNG), with US (radiopharmacy, QLE HQ Austin) and UK (QLE lithium research). LNG is priced in ZAR; commodity He in USD — a real FX axis.

---

Phase B — Measure performance

Lens 5 · Earnings Result

FY2025 (10-K, year ended 2026-12-31… i.e. Dec-31-2025), $000 unless noted:

• Revenue $23,849 (FY24 $4,144) — +475%, but composition is the story (see Lens 4).
• Gross profit $3,405 (14.3% gross margin) — thin; construction is low-margin and isotopes barely contribute.
• Opex $63,313: SG&A $48,238 (FY24 $24,814; +$23.4M, driven by +$12.4M personnel and +$7.0M professional fees), R&D $12,358, acquired IPR&D $2,717.
• Loss from operations $(59,908) (FY24 $(26,354)).
• Other expense $(99,653) — dominated by a $(123,719) non-cash change in fair value of convertible notes, partly offset by +$17,932 change in FV of investments and +$6,790 interest income.
• Net loss before NCI $(159,843); net loss attributable to ASPI $(175,092); EPS $(2.11) on 83.0M wtd shares.
• Company's own adjusted metric (JSE-required): headline loss $(69,184), headline loss/share $(0.83) — i.e., management itself backs out the $123.7M note mark and the $17.9M investment mark. This is the honest read of "operating" loss: roughly $(69)M.

Balance sheet (Dec-31-2025):

• Cash $285,563 + short-term investments $47,745 = ~$333M liquidity.
• Note receivable $32,005 (Renergen loan); Other investments $45,979 (IsoBio/Opeongo/Skyline); Goodwill $8,570; PP&E $33,452.
• Convertible notes payable at fair value $199,323 = the dominant liability (QLE notes). Total liabilities $235,122.
• Total stockholders' equity $262,898 (incl. NCI $58,747); accumulated deficit $(231,265).
• Net cash used in operations $(37,780); investing $(110,794); financing +$371,600 (sold $320M+ of stock). The company is entirely equity/debt-issuance-funded.

Q1 2026 (10-Q, period ended 2026-03-31), $000:

• Revenue $4,180 (vs $1,102 PY) — continuing ops only (Skyline now discontinued).
• Loss from operations $(24,888); net loss attributable $(6,878)$ (a swing helped by a $19.3M gain on Skyline deconsolidation and FV moves).
• Cash fell to $207,346 from $279,572 (continuing-ops basis) — ~$72M used in one quarter (Renergen close, Opeongo $10M, Numed, burn). April 2026 deck cites ~$333M cash — reflecting timing/total-company basis.
• Shares outstanding 125,903,447 (up from 111.7M at YE, +14.27M Renergen consideration shares).

Guidance / tone: no quantitative guidance. Management frames 2026 as the commercial-transition year — first isotope shipments mid-2026, QLE spin, Renergen ramp. Market reaction context: the stock sits ~$4.6–$4.8 (mid-June 2026) vs. analyst targets $11–$13 — the tape is pricing in failure/dilution risk, not the bull deck (Lens 8).

Unusual vs. own history: the FY25 revenue "growth" is an artifact of consolidating then deconsolidating Skyline. Treat the YoY top-line as non-comparable.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts in the research layer (transcripts/ empty). From web coverage of recent communications:

• Consistent management narrative across FY25→Q1'26: "we are transitioning from development to commercial," "first shipments in 2026," "QLE spin unlocks value," "Western alternative to Russian supply." The talking points are stable and milestone-anchored.
• What they started emphasizing in 2026: Renergen/helium integration, the $750M DFC/SBSA funding, and the QLE S-1.
• What recurs and should be discounted: very large prospective TAM claims — "over $30 billion in customer interest for HALEU" and >$15B Lu-177 markets. These are framed as near-in when the underlying capability is years out / unpermitted.
• Tone shift event: Paul Mann took a "temporary leave of absence," then returned as CEO/Exec-Chairman Jan 19 2026 — a governance wobble during the litigation window. Net sentiment read: promotional-optimistic, milestone-heavy, light on hard delivered numbers.

Lens 7 · Comps

ASPI does not fit a clean P/E comp set (pre-revenue on its core, GAAP loss distorted by note marks). The honest framing is by business line, multiples `` or n/a:

Lens 8 · Stock-Price Catalysts (what moves ASPI)

ASPI is a high-beta, narrative-and-short-driven name. Pattern over the last ~2 years:

• Nov 26 2024 — Fuzzy Panda short report ("ASPI Tech is Failed 1990s Tech," AVLIS claims): the catalyst for the price collapse and the securities class action's Oct 30–Nov 26 2024 class window.
• Isotope production milestones (Si-28 commercial production Mar 2025; Yb-176 commissioning Oct 2024) — bullish pops.
• TerraPower / Necsa / Fermi America HALEU agreements — bullish.
• Capital raises ($6.65 → $8.00 → $12.25 stock sales in 2025) — overhang/dilution events.
• Renergen acquisition + $750M DFC funding (Jan 2026) — re-rating catalyst.
• CEO leave + return (Jan 2026) — governance volatility.
• QLE S-1 / spin progress — the single biggest forward catalyst.

What the market actually reacts to: (1) short-seller attacks and litigation, (2) binary milestone proof (first real isotope shipments / first HALEU), (3) financing/dilution. With ~22% short interest, short-squeeze and short-attack dynamics dominate the tape more than fundamentals.

---

Phase C — Judge people & books

Lens 9 · Management

CEO & Executive Chairman: Paul E. Mann — founder. CFO: Heather Kiessling. QLE CEO: Dr. Ryno Pretorius. Post-Renergen, ex-Renergen execs joined: Stefano Marani (President, Electronics & Space) and Nick Mitchell (Co-COO).

1. Track record: Mann built ASPI from inception (2021) through a 2022 IPO to three commissioned enrichment plants and a multi-front M&A program — genuine capability at assembling and financing a complex story. What is not yet on the record: converting any of it into recurring isotope revenue or positive operating cash flow.
2. Skin in the game: Mann owns ~7.0% (7,759,538 shares at 12/31/25; ~9.83M direct after early-2026 grants). Meaningful ownership — but see the selling pattern below.
3. Capital allocation: aggressive serial acquirer/investor — Renergen, Skyline, ECNP, Numed, PET Labs, IsoBio ($5M), Opeongo ($10M), One 30 Seven, Klydon, Molybdos, plus Skyline's own downstream bets (Reemag, a critical-minerals SPV). Funded almost entirely by issuing stock at rising prices in 2025 ($320M+) and convertible notes. ROE/ROIC are deeply negative and not yet a fair test (pre-commercial). The Skyline consolidate-then-deconsolidate round-trip is the capital-allocation event that most undermines confidence (Lens 10).
4. Red flags: (a) a 2,233,555-share grant to Mann vesting from Mar 2026 while a securities-fraud suit naming him is live; (b) persistent open-market insider selling through late-2025/early-2026 ($881k, $933k, 50k-share tranches at $7.76–$8.29) plus a 10b5-1 plan to sell up to ~1.0M more shares (expiry Mar 2027) — much is RSA tax-cover, but the optics of selling into the story are poor; (c) a dense related-party web (IsoBio/Opeongo boards overlap ASP directors; PET Labs leases its facility from an ASP officer; $40M of QLE notes from a related party + parent).
5. Archetype: promoter-founder / dealmaker, not operator. That archetype builds optionality and raises capital superbly in a bull tape; it is exactly the profile that struggles to convert to disciplined commercial execution — and the profile shorts target.

Lens 10 · Forensic Red Flags

This is the lens that matters most for ASPI. Acting as a forensic analyst [all research-layer cites = filings/10-k-2025-q4.md or filings/10-q-2026-q1.md as noted]:

• Revenue quality is poor and was structurally flattering. 76% of FY25 revenue was Skyline construction — a Hong Kong civil-engineering contractor consolidated Aug 2025 (boosting the top line through the period of the big Oct 2025 $199M raise) and deconsolidated Mar 29 2026 via a one-for-one Class B→Class A share swap that dropped QLE below 10% voting, triggering equity-method treatment and a $19.3M gain on deconsolidation. Consolidating a low-multiple contractor into an "isotope" story, then unwinding it shortly after the raise, is a serious quality-of-earnings flag.
• The headline GAAP loss is a non-cash artifact. $(123.7)M of the FY25 loss is the change in fair value of QLE convertible notes, which convert at 80% of a future QLE-IPO price subject to a valuation cap — so the more likely / higher-valued the QLE IPO looks, the larger the GAAP liability/loss. Management's own headline loss backs it out to $(69.2)M. Not fraud — but it makes the income statement nearly useless without adjustment, and it is opaque (fair-value, model-driven, Level 3-ish).
• MATERIAL WEAKNESS in ICFR — disclosed and unremediated. Both disclosure controls and ICFR were concluded NOT EFFECTIVE as of 12/31/2025. Three weaknesses: (1) lack of formal control documentation + consistent execution; (2) insufficient finance/accounting personnel with appropriate knowledge/experience; (3) IT logical security & privileged access. Remediation "during 2026," not assured. For a company booking a $124M fair-value mark and $46M of unlisted investments, weak controls are materially elevated risk.
• Auditor: EisnerAmper LLP (PCAOB ID 274, auditor since 2022), clean unqualified opinion, NO going-concern paragraph (the ~$333M cash removed that doubt). But the auditor explicitly did not audit ICFR (EGC exemption).
• Investment marks flatter "other income." A +$17.9M FV gain on investments (IsoBio/Opeongo/Skyline) ran through FY25 other income; these are illiquid, self-originated stakes in companies with overlapping board members — mark-to-model on related-party positions.
• Customer concentration: four customers = 28/23/18/13% of AR; two Skyline construction customers were 32.2% and 13.7% of FY25 consolidated revenue (now departed with the deconsolidation).
• Renergen debt covenants: DFC/IDC facilities carry Debt/EBITDA ≤3.0, current ratio ≥1.0, DSCR ≥1.3, reserve-tail ≥25% — measurable post-Project-Completion; a pre-cash-flow asset under a $1.16B build carries real covenant risk. Multiple legacy disputes (Molopo loan litigation to 2030; AIRSOL/SOL convertible debentures in repayment dispute; SBSA loan past original maturity, being renegotiated) ride along with Renergen.

Regulatory findings (required sub-section):

• SEC EDGAR EFTS (LR + AAER): No Litigation Releases and No AAERs naming ASP Isotopes in the 2021-06-18 → 2026-06-18 window.
• 10-K Item 3 (Legal Proceedings) — material, ongoing:
• Securities class action — Corredor / Leone v. ASP Isotopes, et al., S.D.N.Y. (1:24-cv-09253), filed Dec 4 2024 for the Oct 30–Nov 26 2024 class period; alleges §10(b)/§20(a)/Rule 10b-5 false-or-misleading statements by the company, CEO and CFO. On Dec 4 2025 the court DENIED IN PART the motion to dismiss AND GRANTED class certification — an unusually adverse procedural posture (most §10(b) cases are dismissed at the MTD). The parties reached an agreement-in-principle to settle (April 2026), subject to court approval; terms not yet disclosed. A settlement caps the tail but is itself a cash/credibility cost and an implicit acknowledgment of litigation strength.
• Two derivative actions — Jenis v. Mann (N.D. Tex., 3:26-cv-251) and Stewart v. Mann (S.D.N.Y., 1:26-cv-1712), filed Jan/Mar 2026 against board members on the same allegations; still live, defendants not yet responded.
• Non-SEC enforcement (web): no FTC/DOJ/FDA/CFPB enforcement actions, consent decrees, fines or penalties against ASP Isotopes surfaced. The Fuzzy Panda short report (Nov 2024) is research/opinion, not a regulatory action.
• Summary: No SEC enforcement to date, but active, materially advanced securities-fraud litigation (settling) + two live derivative suits + a disclosed unremediated material weakness = a genuinely elevated forensic/legal risk profile. The shorts' thesis is not frivolous; a court let it past dismissal.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

ASPI cannot be cleanly EPS-modeled — it is pre-revenue on its core, GAAP EPS is dominated by a model-driven note mark, and the business mix just changed (Skyline out, Renergen in). I model the honest operating loss (≈ headline loss) and the cash runway, not a fabricated EPS path. All `` with arithmetic; inputs labeled.

Anchor actuals: FY25 headline (operating) loss ≈ $(69)M; operating cash burn $(37.8)M; liquidity ~$333M at YE25 → $207M cash at 3/31/26 after a ~$72M Q1 outflow.

• Runway: if normalized cash burn settles at ~$120–160M/yr, then $207M cash funds roughly 4–6 quarters before Phase-2 build spend — i.e., another equity raise is highly likely within 12 months, independent of the conditionally-committed (not yet drawn) $750M project debt.
• Revenue path (continuing ops, base/bull/bear), $M:
• Base FY2026 ~$25–35M: radiopharmacy ~$25M + first modest isotope shipments (single-digit $M) + early helium/LNG. Still deeply loss-making.
• Bull FY2027 ~$80–150M: Yb-176 + Si-28 reach commercial scale, Renergen Phase-1 helium runs reliably, HALEU still pre-revenue. Path to segment-level gross profit on isotopes.
• Bear FY2026–27 <$25M: isotope shipments slip again (this would be the third "next year" promise), helium under-produces (consistent with its leak/ISO-fill history ), and the company raises equity at a depressed price.
• GAAP EPS: n/a — not meaningfully forecastable; the convertible-note FV mark will continue to swing GAAP wildly with QLE-IPO probability. Track headline loss/share instead (FY25 $(0.83)).

Brier forecast: per --watchlist unattended rules, I am not logging a forecast.ts create (reserve that for a genuinely committed base case). The scoreable binary I'd track if promoting: "ASPI reports its first commercial enriched-isotope (Yb-176 or Si-28) shipment revenue on or before the Q3-2026 10-Q (filed by ~2026-11-15)" — my subjective p ≈ 0.55 (they've slipped before; but plants are commissioned and POs exist).

Lens 12 · Bull vs Bear

Bull case (narrative): ASPI is the West's emerging second source for three Russia-monopoly critical materials at the exact moment supply-chain de-risking is policy. Yb-176 → Lu-177 is a supply-constrained, >$15B/decade oncology pull with documented patient shortages and only Rosatom supplying today; ASP claims sole-Western-supplier status with plants commissioned. Si-28 feeds the silicon-qubit/advanced-semi wave with signed POs from marquee buyers. QLE is a free call option — a confidential S-1 is filed, TerraPower is anchored, and a spin distributes value directly to ASPI holders while ASP keeps a 10% perpetual royalty. Renergen adds a real, DFC-funded ($750M) helium/LNG asset with a structural grade advantage into a helium-short world. ~$333M cash, 22% short interest, and a $11–$13 analyst target vs. a ~$4.7 price = asymmetric upside on the first proof-of-commercial print.

Bear case (2–3 permanent-impairment risks):

1. Execution slips again and the "Western monopoly" never converts to scale. Three straight years of "shipments next year"; helium has a documented leak/under-production track record; HALEU is unpermitted and years behind Centrus/Urenco. If isotope revenue stays sub-scale into 2027, the entire thesis is just a perpetually-funded R&D program.
2. Dilution is structural. The model is issue equity → acquire → repeat; $207M cash funds ~4–6 quarters before a $1.16B Phase-2 build; the QLE notes convert into more shares; raises will come at whatever price the tape allows — and the tape is weak.
3. Governance/accounting impairs credibility (and the multiple). A court let a securities-fraud case past dismissal and certified a class (now settling); two derivative suits are live; ICFR is a disclosed unremediated material weakness; the Skyline consolidate-then-deconsolidate round-trip and related-party investment web are exactly what a forensic short flags. Any one re-rates the name down.

Pre-mortem (18 months out, thesis broke): It's late 2027. Isotope shipments came but stayed at low-single-digit $M; Yb-176 yields/qualification lagged; Renergen helium under-produced through another technical fault; QLE's IPO was pulled or priced poorly in a soft SMR-fuel tape; the company raised equity twice more near lows; the class-action settlement and a derivative settlement drained cash and headlines. The stock is a fraction of today. The break was not the science failing outright — it was time, dilution, and credibility compounding faster than commercial revenue.

Are multiples too high? There are no earnings multiples to be "too high." The risk is the opposite: the $11–$13 targets assume successful commercial conversion that the ~$4.7 tape plainly doubts. The market is the skeptic here, not the optimist.

Contrarian view (what the market may be refusing to see): the Yb-176/Lu-177 leg alone could be worth more than today's whole EV if it converts — a genuine Western monopoly into a $15B/decade, shortage-driven, high-margin medical market is rare. The market is so consumed by the short-report/litigation/dilution narrative that it may be under-pricing the one leg with a real, near-term, defensible monopoly. The asymmetry is real if you can stomach the governance risk and the dilution.

Lens 13 · Devil's Advocate (short-seller)

Short thesis: ASPI is a serial-promotion roll-up dressed as a deep-tech monopoly, and a court has already validated that investors were allegedly misled.

• Where revenue is concentrated / what breaks it: there is no core revenue — 76% of FY25 was a construction contractor they deconsolidated months later, and isotopes are still $0. The "revenue growth" is an accounting illusion. If you underwrite only delivered isotope revenue, you're paying ~$0.6B EV for a ~$5.6M radiopharmacy and a pile of promises.
• Why the moat is weaker than bulls think: on HALEU — the leg the deck pumps hardest with "$30B of customer interest" — ASP has enriched zero uranium and lacks permission to even test, while Centrus has delivered 900+ kg to DOE and Urenco is NRC-authorized. That's not a moat; that's a latecomer with a press release.
• Most dangerous competitor bulls underestimate: Urenco — it can already separate Si-28 at scale and is the Western LEU+/HALEU incumbent. ASP is squeezed on both its semi and its nuclear legs by one well-capitalized state-backed player.
• Worst capital-allocation / governance: consolidate Skyline right before a $199M raise, deconsolidate after for a $19.3M gain; mark related-party investments up $17.9M through income; grant the CEO 2.2M shares while he's a fraud-suit defendant and selling stock; run on a disclosed material weakness with "insufficient accounting personnel."
• Assumptions that must hold for today's price: that this time the shipments are real and scale; that helium runs reliably (it hasn't); that the QLE spin prices well; that they don't dilute at the lows; that the litigation settles cheaply. Each is a coin-flip; the product is small.
• −20–30% growth shock: with no earnings to compress, a growth disappointment hits via another dilutive raise at a lower price — the most likely value-destruction path.
• Single scenario that permanently impairs: a failed/under-yield Yb-176 qualification plus a Renergen technical failure that trips a DFC covenant — the two "real" legs break together, the QLE optionality is left as the only story, and the equity recapitalizes. Plausibility: moderate, not remote — and the shorts (~22% of float) are betting on exactly this compounding.

Lens 14 · Management Questions (ordered by information value)

1. Of FY2025 revenue, $0 was enriched isotopes. What is the specific dollar value and customer of your first commercial Yb-176 and Si-28 shipments, and what hard yield/purity/qualification milestone gates that revenue? (The whole thesis turns on this number.)
2. You consolidated Skyline in Aug 2025 and deconsolidated it in Mar 2026 for a $19.3M gain, right around a $199M equity raise. Walk us through the business rationale and timing — why consolidate a Hong Kong contractor into an isotope company at all?
3. ICFR was concluded not effective with insufficient accounting personnel. What is the dated remediation plan, who have you hired, and will it be remediated before FY2026 close — given you carry a $124M fair-value note mark and $46M of unlisted investments?
4. $207M cash at 3/31/26, a $1.16B Phase-2 build, and ~$120–160M annual burn. What is your honest cash runway, and when and at what size do you expect the next equity raise — before or after the QLE spin?
5. The QLE convertible notes drove a $124M non-cash loss and convert at 80% of the IPO price. What QLE valuation and IPO timing are you underwriting, and what is the fully-diluted ASPI share count after conversion?
6. On HALEU you cite "$30B of customer interest," yet you've enriched no uranium and lack test permission while Centrus and Urenco are years ahead. What is your realistic first-HALEU-kilogram date, and why will buyers choose an unpermitted South African source?
7. Renergen helium has a documented history of leaks and ISO-container fill problems and is "producing at a reduced rate." What is current sustained liquid-helium output vs. the 350 kg/day Phase-1 nameplate, and what's the path to nameplate?
8. The $750M DFC/SBSA debt is conditionally approved and undrawn. What conditions precedent remain, and what happens to Phase 2 if it doesn't fund on schedule?
9. You've made 8+ acquisitions/investments in 18 months, several with overlapping board members (IsoBio, Opeongo) and a related-party lease (PET Labs). How do you govern related-party conflicts, and who independently values these stakes?
10. The securities class action survived dismissal, was class-certified, and is settling. What are the expected settlement terms and cash cost, and what specifically did you change about disclosure?
11. You took a leave of absence and returned as CEO in Jan 2026. What prompted it, and what is the succession/depth plan given you're also a litigation defendant?
12. You're selling stock under a 10b5-1 plan (up to ~1M shares) while issuing yourself 2.2M shares. Reconcile that with conviction in the commercial inflection you're promoting.
13. Renergen's debt sits under restrictive DFC/IDC covenants (Debt/EBITDA ≤3.0, DSCR ≥1.3) on a pre-cash-flow asset. What is the covenant-compliance plan through Phase-2 construction?
14. You intend to split into Specialist Isotopes and Nuclear Fuels (QLE). Post-split, what is the standalone funding and path-to-profitability for the remaining isotope business on ~$5–35M revenue?
15. Name the single isotope program you're most confident becomes a durable, cash-generative monopoly within 24 months — and what's the one thing that kills it?

---